Shire–Argen-X: SIMPLE antibody discovery platform, 201203– collab €na create antibodies for rare genetic disease targets of Shire

	Period	2012-03-01
	Successor	Shire–Argen-X: SIMPLE antibody discovery platform, 201301– collab expansion to incl new therapeutic indication
	Partner, 1st	Argen-X B.V.
	Group	Argen-X (Group)
	Product	SIMPLE Antibody™ discovery platform
	Product 2	therapeutic antibody

Argen-X B.V.. (2/29/12). "Press Release: Argen-X Enters into a Therapeutic Antibody Alliance with Shire. Human Antibody Product Collaboration in Rare Diseases". Rotterdam & Ghent.

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire.

Using its cutting edge SIMPLE Antibody™ discovery technology, arGEN-X will isolate and characterize human antibodies against the targets that Shire has identified and that are known to contribute to the pathophysiology of severe, rare genetic diseases. arGEN-X will also bring its state-of-the-art antibody capabilities to the collaboration for the preclinical characterization of therapeutic leads. Shire has the option to license the most promising leads for further preclinical and clinical development and commercialization worldwide.

Under the terms of the agreement, arGEN-X will receive an upfront technology access fee, research funding and preclinical success payments. In return for its option to develop and commercialize products on an exclusive basis, Shire will pay fees, milestones and royalties on product sales. Specific details of the financial terms were not disclosed.

Tim Van Hauwermeiren, CEO of arGEN-X, said, "We are delighted to pioneer human antibodies as novel, first-in-class therapies for rare diseases with a partner of Shire's calibre. Shire's depth of experience in protein-based therapies is the perfect complement to our own discovery capabilities. We are confident that our SIMPLE Antibody™ platform, which consistently delivers antibodies of therapeutic quality against complex targets often intractable with other technologies, will bring significant value to this alliance. We believe this alliance represents an industry first and we are looking forward to an exciting and productive collaboration with Shire."

"As a leader in innovative therapies for rare diseases, Shire is continuing to apply new technologies to address the needs of patients," said Philip J. Vickers, Senior Vice President, Research and Development, Shire Human Genetic Therapies (HGT). "Monoclonal antibody therapy is an underutilized approach to the treatment of rare diseases, and this novel platform has the potential to bring multiple drug candidates into our early-stage pipeline. Partnerships such as this one with arGEN-X are an important part of our strategy to bring new therapies to those suffering from rare diseases worldwide."

Record changed: 2013-01-08

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Shire–Argen-X: SIMPLE antibody discovery platform, 201203– collab €na create antibodies for rare genetic disease targets of Shire

Argen-X B.V.. (2/29/12). "Press Release: Argen-X Enters into a Therapeutic Antibody Alliance with Shire. Human Antibody Product Collaboration in Rare Diseases". Rotterdam & Ghent.

More documents for Shire (Group)